{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:00:41Z","timestamp":1786122041854,"version":"build-2736575974"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"DOI":"10.1186\/s13014-026-02869-y","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:14:16Z","timestamp":1780503256000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of radiotherapy of hepatocellular carcinoma: a retrospective analysis"],"prefix":"10.1186","volume":"21","author":[{"given":"Volker","family":"Rudat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maixuan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew X.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"issue":"1","key":"2869_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.soc.2023.06.004","volume":"33","author":"NE Rich","year":"2024","unstructured":"Rich NE. Changing epidemiology of hepatocellular carcinoma within the United States and worldwide. Surg Oncol Clin N Am [Internet]. 2024;33(1):1\u201312. Available from: https:\/\/doi.org\/10.1016\/j.soc.2023.06.004. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320723000558. 2024 Oct 24.","journal-title":"Surg Oncol Clin N Am"},{"issue":"3","key":"2869_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clinicians [Internet]. 2024;74(3):229\u201363. Available from: https:\/\/doi.org\/10.3322\/caac.21834. https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.3322\/caac.21834. 2024 Nov 23.","journal-title":"CA Cancer J Clinicians"},{"issue":"4","key":"2869_CR3","doi-asserted-by":"publisher","first-page":"756","DOI":"10.3350\/cmh.2024.0318","volume":"30","author":"D Kim","year":"2024","unstructured":"Kim D, Manikat R, Wijarnpreecha K, Cholankeril G, Ahmed A. Burden of mortality from hepatocellular carcinoma and biliary tract cancers by race and ethnicity and sex in US, 2018\u20132023. Clin Mol Hepatol [Internet]. 2024;30(4):756\u201370. Available from: https:\/\/doi.org\/10.3350\/cmh.2024.0318. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC11540356\/. 2024 Dec 26.","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"2869_CR4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00261-022-03690-3","volume":"48","author":"D Yang","year":"2022","unstructured":"Yang D, Lin K, Wang Y, Xie X, Xie X, Zhuang B. Stereotactic body radiation therapy versus radiofrequency ablation in hepatocellular carcinoma: an up-date meta-analysis. Abdom Radiol N Y. 2022;48(1):399\u2013410. https:\/\/doi.org\/10.1007\/s00261-022-03690-3.","journal-title":"Abdom Radiol N Y"},{"key":"2869_CR5","doi-asserted-by":"crossref","unstructured":"Jia S, Lao N, Boldt RG, Mujoomdar A, Chow R, Simone C, et al. Stereotactic body radiation therapy (SBRT) versus transarterial chemoembolization (TACE) for treatment of hepatocellular carcinoma: a meta-analysis of propensity Matched studies. Univ Tor Med J [Internet]. 2024. https:\/\/jps.library.utoronto.ca\/index.php\/utmj\/article\/view\/41240. 2024 Dec 3.","DOI":"10.33137\/utmj.v101i1.41240"},{"issue":"3","key":"2869_CR6","doi-asserted-by":"publisher","first-page":"388","DOI":"10.33371\/ijoc.v18i3.1190","volume":"18","author":"A Giselvania","year":"2024","unstructured":"Giselvania A, Sekarutami SM, Munandar A, Halim DA, Wijovi F. The role of Stereotactic body radiation therapy for hepatocellular carcinoma patients: a literature review. Indones J Cancer [Internet]. 2024;18(3):388\u201397. Available from: 10.33371\/ijoc.v18i3.1190. 2024 Nov 27.","journal-title":"Indones J Cancer"},{"issue":"5","key":"2869_CR7","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.ijrobp.2023.07.001","volume":"118","author":"C Ning","year":"2024","unstructured":"Ning C, Zhang X, Wang Y, Yang X, Yang X, Chao J, et al. Radiation therapy with combination therapy of immune checkpoint inhibitors and antiangiogenic therapy for hepatocellular carcinoma. Int J Multiling Radiat Oncol*Biol*Phys [Internet]. 2024;118(5):1461\u201371. Available from: https:\/\/doi.org\/10.1016\/j.ijrobp.2023.07.001. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301623076265. 2024 Apr 8.","journal-title":"Int J Multiling Radiat Oncol*Biol*Phys"},{"issue":"4","key":"2869_CR8","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.semradonc.2018.06.006","volume":"28","author":"FK Keane","year":"2018","unstructured":"Keane FK, Hong TS, Zhu AX. Evolving systemic therapy in hepatocellular carcinoma: current Management and opportunities for integration with radiotherapy. Semin Radiat Oncol [Internet]. 2018;28(4):332\u201341. Available from: https:\/\/doi.org\/10.1016\/j.semradonc.2018.06.006. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429618300511. 2024 Nov 25.","journal-title":"Semin Radiat Oncol"},{"issue":"4","key":"2869_CR9","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1159\/000523997","volume":"11","author":"J Sun","year":"2022","unstructured":"Sun J, Guo R, Bi X, Wu M, Tang Z, Lau WY, et al. Guidelines for diagnosis and treatment of hepatocellular carcinoma with Portal vein tumor thrombus in China (2021 edition). Liver Cancer [Internet]. 2022;11(4):315\u201328. Available from: 10.1159\/000523997. 2024 Nov 27.","journal-title":"Liver Cancer"},{"issue":"6","key":"2869_CR10","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.annonc.2021.02.014","volume":"32","author":"A Vogel","year":"2021","unstructured":"Vogel A, Martinelli E, Vogel A, Cervantes A, Chau I, Daniele B, et al. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO clinical Practice guidelines. Ann Oncol [Internet]. 2021;32(6):801\u201305. Available from: https:\/\/doi.org\/10.1016\/j.annonc.2021.02.014. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375342100154X. 2024 Nov 2.","journal-title":"Ann Oncol"},{"key":"2869_CR11","unstructured":"NCCN 29.9. 2024. Hepatobiliary Carcinoma. NCCN. 2024."},{"key":"2869_CR12","unstructured":"Langer T. S3-Leitlinie Diagnostik und Therapie des Hepatozellul\u00e4ren Karzinoms und bili\u00e4rer Karzinome. 2024."},{"issue":"1","key":"2869_CR13","doi-asserted-by":"publisher","first-page":"101269","DOI":"10.1016\/j.jceh.2023.08.005","volume":"14","author":"A Kumar","year":"2024","unstructured":"Kumar A, Acharya SK, Singh SP, Duseja A, Madan K, Shukla A, et al. 2023 Update of Indian National Association for study of the liver Consensus on Management of Intermediate and advanced hepatocellular carcinoma: the Puri III recommendations. J Clin Exp Hepatol [Internet]. 2024 [cited 2024 Nov 9], 2024;14(1):101269. Available from: https:\/\/doi.org\/10.1016\/j.jceh.2023.08.005. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0973688323006904.","journal-title":"J Clin Exp Hepatol"},{"issue":"6","key":"2869_CR14","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, et al. AASLD Practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology [Internet]. 2023;78(6):1922\u201365. Available from: 10.1097\/HEP.0000000000000466. 2024 Nov 27.","journal-title":"Hepatology"},{"issue":"3","key":"2869_CR15","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer-F\u00e0brega J, Burrel M, Garcia-Criado \u00c1, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Educ Chang Hepatol [Internet]. 2022;76(3):681\u201393. Available from: https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827821022236. 2024 Nov 1.","journal-title":"J Educ Chang Hepatol"},{"issue":"3","key":"2869_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000514174","volume":"10","author":"M Kudo","year":"2021","unstructured":"Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, et al. Management of hepatocellular carcinoma in Japan: JSH Consensus statements and recommendations 2021 Update. Liver Cancer [Internet]. 2021;10(3):181\u2013223. Available from: 10.1159\/000514174. 2024 Nov 30.","journal-title":"Liver Cancer"},{"issue":"1","key":"2869_CR17","doi-asserted-by":"publisher","first-page":"17018","DOI":"10.1038\/s41598-023-44320-2","volume":"13","author":"V Rudat","year":"2023","unstructured":"Rudat V, Shi Y, Zhao R, Xu S, Yu W. Setup accuracy and margins for surface-guided radiotherapy (SGRT) of head, thorax, abdomen, and pelvic target volumes. Sci Rep. 2023;13(1):17018. https:\/\/doi.org\/10.1038\/s41598-023-44320-2.","journal-title":"Sci Rep"},{"key":"2869_CR18","doi-asserted-by":"crossref","unstructured":"Hijazi H, Campeau M-P, Roberge D, Donath D, Lapointe R, Vandenbroucke-Menu F, et al. Stereotactic body radiotherapy for Inoperable liver tumors: results of a single institutional experience. Cureus [Internet]. 2016;8:e935. Available from: https:\/\/doi.org\/10.7759\/cureus.935. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5258195\/. 2024 Nov 9.","DOI":"10.7759\/cureus.935"},{"issue":"13","key":"2869_CR19","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1002\/cncr.30008","volume":"122","author":"A Takeda","year":"2016","unstructured":"Takeda A, Sanuki N, Tsurugai Y, Iwabuchi S, Matsunaga K, Ebinuma H, et al. Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation. Cancer [Internet]. 2016;122(13):2041\u201349. Available from: 10.1002\/cncr.30008. 2024 Nov 9.","journal-title":"Cancer"},{"issue":"3","key":"2869_CR20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/jso.24661","volume":"116","author":"NG Berger","year":"2017","unstructured":"Berger NG, Tanious MN, Hammad AY, Miura JT, Mogal H, Clarke CN, et al. External radiation or ablation for solitary hepatocellular carcinoma: a survival analysis of the SEER database. J Surg Oncol [Internet]. 2017;116(3):307\u201312. Available from: 10.1002\/jso.24661. 2024 Nov 8.","journal-title":"J Surg Oncol"},{"issue":"3","key":"2869_CR21","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.ijrobp.2017.02.095","volume":"98","author":"T-S Su","year":"2017","unstructured":"Su T-S, Liang P, Liang J, Lu H-Z, Jiang H-Y, Cheng T, et al. Long-term survival analysis of Stereotactic ablative radiotherapy versus liver resection for small hepatocellular carcinoma. Int J Multiling Radiat Oncol*Biol*Phys [Internet]. 2017;98(3):639\u201346. Available from: https:\/\/doi.org\/10.1016\/j.ijrobp.2017.02.095; https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301617304984. 2024 Nov 7.","journal-title":"Int J Multiling Radiat Oncol*Biol*Phys"},{"key":"2869_CR22","doi-asserted-by":"crossref","unstructured":"Kimura T. Comparison of Stereotactic body radiation therapy combined with or without transcatheter arterial chemoembolization for patients with small hepatocellular carcinoma ineligible for resection or ablation therapies. 2018. [2024 Nov 5]: https:\/\/journals.sagepub.com\/doi\/epub\/10.1177\/1533033818783450.","DOI":"10.1177\/1533033818783450"},{"issue":"2","key":"2869_CR23","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.surg.2018.03.006","volume":"164","author":"R Nakano","year":"2018","unstructured":"Nakano R, Ohira M, Kobayashi T, Ide K, Tahara H, Kuroda S, et al. Hepatectomy versus stereotactic body radiotherapy for primary early hepatocellular carcinoma: a propensity-matched analysis in a single institution. Surgery [Internet]. 2018;164(2):219\u201326. Available from: https:\/\/doi.org\/10.1016\/j.surg.2018.03.006. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039606018301296. 2024 Nov 7.","journal-title":"Surgery"},{"issue":"6","key":"2869_CR24","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1200\/JCO.2017.75.3228","volume":"36","author":"DJ Rajyaguru","year":"2018","unstructured":"Rajyaguru DJ, Borgert AJ, Smith AL, Thomes RM, Conway PD, Halfdanarson TR, et al. Radiofrequency ablation versus Stereotactic body radiotherapy for localized hepatocellular carcinoma in nonsurgically managed patients: analysis of the National Cancer database. JCO [Internet]. 2018;36(6):600\u201308. Available from: 10.1200\/JCO.2017.75.3228. 2024 Nov 7.","journal-title":"JCO"},{"issue":"1","key":"2869_CR25","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ijrobp.2019.12.004","volume":"107","author":"J Durand-Labrunie","year":"2020","unstructured":"Durand-Labrunie J, Baumann A-S, Ayav A, Laurent V, Boleslawski E, Cattan S, et al. Curative irradiation treatment of hepatocellular carcinoma: a multicenter phase 2 trial. Int J Multiling Radiat Oncol*Biol*Phys [Internet]. 2020;107(1):116\u201325. Available from: https:\/\/doi.org\/10.1016\/j.ijrobp.2019.12.004. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301619345122. 2024 Nov 9.","journal-title":"Int J Multiling Radiat Oncol*Biol*Phys"},{"issue":"6","key":"2869_CR26","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1002\/hep.30591","volume":"69","author":"K Hara","year":"2019","unstructured":"Hara K, Takeda A, Tsurugai Y, Saigusa Y, Sanuki N, Eriguchi T, et al. Radiotherapy for hepatocellular carcinoma Results in comparable survival to radiofrequency ablation: a propensity score analysis. Hepatology [Internet]. 2019;69(6):2533\u201345. Available from: https:\/\/doi.org\/10.1002\/hep.30591. https:\/\/journals.lww.com\/01515467-201906000-00024. 2024 Nov 7.","journal-title":"Hepatology"},{"key":"2869_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/4835653","volume":"2020","author":"Y Fu","year":"2020","unstructured":"Fu Y, Xi M, Pan Y, Chen J, Wang J, Liu S, et al. Stereotactic body radiotherapy as a salvage therapy after incomplete radiofrequency ablation for hepatocellular carcinoma: a retrospective cohort study. J Oncol [Internet]. 2020 [cited 2024 Nov 9], 2020:1\u20139. Available from: https:\/\/doi.org\/10.1155\/2020\/4835653. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7275213\/.","journal-title":"J Oncol"},{"issue":"11","key":"2869_CR28","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1111\/jgh.15011","volume":"35","author":"S Park","year":"2020","unstructured":"Park S, Jung J, Cho B, Kim SY, Yun S, Lim Y, et al. Clinical outcomes of stereotactic body radiation therapy for small hepatocellular carcinoma. J Gastro Hepatol [Internet]. 2020;35(11):1953\u201359. Available from: 10.1111\/jgh.15011. 2024 Nov 9.","journal-title":"J Gastro Hepatol"},{"key":"2869_CR29","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3389\/fonc.2020.00347","volume":"10","author":"T-S Su","year":"2020","unstructured":"Su T-S, Liang P, Zhou Y, Huang Y, Cheng T, Qu S, et al. Stereotactic body radiation therapy vs. Transarterial Chemoembolization in Inoperable Barcelona clinic liver cancer stage a hepatocellular carcinoma: a retrospective, propensity-Matched analysis. Front Oncol [Internet]. 2020;10:347. Available from: https:\/\/doi.org\/10.3389\/fonc.2020.00347. https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00347\/full. 2024 Apr 5.","journal-title":"Front Oncol"},{"issue":"5","key":"2869_CR30","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1007\/s12072-020-10088-0","volume":"14","author":"J Sun","year":"2020","unstructured":"Sun J, Wang Q, Hong Z-X, Li W-G, He W-P, Zhang T, et al. Stereotactic body radiotherapy versus hepatic resection for hepatocellular carcinoma (\u2264 5 cm): a propensity score analysis. Hepatol Int [Internet]. 2020;14(5):788\u201397. Available from: 10.1007\/s12072-020-10088-0. 2024 Nov 7.","journal-title":"Hepatol Int"},{"issue":"4","key":"2869_CR31","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3350\/cmh.2020.0038","volume":"26","author":"SM Yoon","year":"2020","unstructured":"Yoon SM, Kim SY, Lim Y-S, Kim KM, Shim JH, Lee D, et al. Stereotactic body radiation therapy for small (\u22645 cm) hepatocellular carcinoma not amenable to curative treatment: results of a single-arm, phase II clinical trial. Clin Mol Hepatol [Internet]. 2020;26(4):506\u201315. Available from: 10.3350\/cmh.2020.0038. 2024 Oct 24.","journal-title":"Clin Mol Hepatol"},{"issue":"7","key":"2869_CR32","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1111\/jgh.15442","volume":"36","author":"Y Jeong","year":"2021","unstructured":"Jeong Y, Lee KJ, Lee SJ, Shin YM, Kim M, Lim Y, et al. Radiofrequency ablation versus stereotactic body radiation therapy for small (\u2264 3 cm) hepatocellular carcinoma: a retrospective comparison analysis. J Gastro Hepatol [Internet]. 2021;36(7):1962\u201370. Available from: 10.1111\/jgh.15442. 2024 Nov 7.","journal-title":"J Gastro Hepatol"},{"issue":"4","key":"2869_CR33","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/hepr.13595","volume":"51","author":"T Kimura","year":"2021","unstructured":"Kimura T, Takeda A, Sanuki N, Ariyoshi K, Yamaguchi T, Imagumbai T, et al. Multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma: the STRSPH study. Hepatol Res [Internet]. 2021;51(4):461\u201371. Available from: 10.1111\/hepr.13595. 2024 Nov 9.","journal-title":"Hepatol Res"},{"issue":"7","key":"2869_CR34","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1111\/1754-9485.13309","volume":"65","author":"MD Shanker","year":"2021","unstructured":"Shanker MD, Moodaley P, Soon W, Liu HY, Lee YY, Pryor DI. Stereotactic ablative radiotherapy for hepatocellular carcinoma: a systematic review and meta-analysis of local control, survival and toxicity outcomes. J Med Imag RAD Onc [Internet]. 2021;65(7):956\u201368. Available from: 10.1111\/1754-9485.13309. 2024 Sep 18.","journal-title":"J Med Imag RAD Onc"},{"key":"2869_CR35","doi-asserted-by":"crossref","unstructured":"Ueno M, Takabatake H, Itasaka S, Kayahara T, Morimoto Y, Yamamoto H, et al. Stereotactic body radiation therapy versus radiofrequency ablation for single small hepatocellular carcinoma: a propensity-score matching analysis of their impact on liver function and clinical outcomes. J Gastrointest Oncol [Internet]. 2021. https:\/\/jgo.amegroups.org\/article\/view\/56237. 2024 Nov 5.","DOI":"10.21203\/rs.3.rs-228801\/v1"},{"key":"2869_CR36","doi-asserted-by":"crossref","unstructured":"Ji R, Ng KK, Chen W, Yang W, Zhu H, Cheung T-T, et al. Comparison of clinical outcome between stereotactic body radiotherapy and radiofrequency ablation for unresectable hepatocellular carcinoma. Med (Baltim) [Internet]. 2022;101(4):e28545. Available from: 10.1097\/MD.0000000000028545. 2024 Nov 8.","DOI":"10.1097\/MD.0000000000028545"},{"issue":"11","key":"2869_CR37","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1097\/MEG.0000000000002442","volume":"34","author":"HS Shin","year":"2022","unstructured":"Shin HS, Hwan Lee S, Jun BG, Kim HS, Kang SH, Park JY, et al. Stereotactic body radiotherapy versus radiofrequency ablation as initial treatment of small hepatocellular carcinoma. Eur J Gastroenterol Hepatol [Internet]. 2022;34(11):1187. Available from: https:\/\/doi.org\/10.1097\/MEG.0000000000002442. https:\/\/journals.lww.com\/eurojgh\/abstract\/2022\/11000\/stereotactic_body_radiotherapy_versus.14.aspx. 2024 Nov 5.","journal-title":"Eur. J. Gastroenterol. Hepatol"},{"key":"2869_CR38","doi-asserted-by":"crossref","unstructured":"Lee VH-F, Vardhanabhuti V, Wong TC-L, Lam K-O, Choi HC-W, Chiu KW-H, et al. Stereotactic body radiotherapy and liver transplant for liver Cancer: a nonrandomized controlled trial. JAMA Netw Open [Internet]. 2024;7(6):e2415998. Available from: https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.15998. https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2819744. 2024 Nov 9.","DOI":"10.1001\/jamanetworkopen.2024.15998"},{"key":"2869_CR39","first-page":"100767","volume":"46","author":"D-X Zheng","year":"2024","unstructured":"Zheng D-X, Chen Y-X, Sun J, Hu Y, Yang P, Zhang Y, et al. Stereotactic body radiation therapy in patients with centrally located hepatocellular carcinoma: a retrospective, single-arm, multi-center study. Clin Transl Radiat Oncol [Internet]. 2024;46:100767. Available from: https:\/\/doi.org\/10.1016\/j.ctro.2024.100767. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630824000442. 2024 Oct 24.","journal-title":"Clin Transl Radiat Oncol"},{"issue":"2","key":"2869_CR40","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.prro.2023.08.016","volume":"14","author":"TK Yanagihara","year":"2024","unstructured":"Yanagihara TK, Tepper JE, Moon AM, Barry A, Molla M, Seong J, et al. Defining minimum treatment parameters of ablative radiation therapy in patients with hepatocellular carcinoma: an expert Consensus. Pract Radiat Oncol [Internet]. 2024;14(2):134\u201345. Available from: https:\/\/doi.org\/10.1016\/j.prro.2023.08.016. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187985002300276X. 2024 Oct 24.","journal-title":"Pract Radiat Oncol"},{"issue":"8","key":"2869_CR41","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.3390\/cancers15082330","volume":"15","author":"E Birgin","year":"2023","unstructured":"Birgin E, Hetjens S, Tam M, Correa-Gallego C, Rahbari NN. Stereotactic body radiation therapy versus Surgical resection for stage I\/II hepatocellular carcinoma. Cancers [Internet]. 2023;15(8):2330. Available from: https:\/\/doi.org\/10.3390\/cancers15082330. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10136632\/. 2024 Sep 5.","journal-title":"Cancers"},{"issue":"2","key":"2869_CR42","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ijrobp.2020.09.038","volume":"109","author":"N Kim","year":"2021","unstructured":"Kim N, Cheng J, Huang W-Y, Kimura T, Zeng ZC, Lee VHF, et al. Dose-response relationship in Stereotactic body radiation therapy for hepatocellular carcinoma: a pooled analysis of an Asian liver radiation therapy group study. Int J Multiling Radiat Oncol*Biol*Phys [Internet]. 2021;109(2):464\u201373. Available from: https:\/\/doi.org\/10.1016\/j.ijrobp.2020.09.038. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301620343108. 2024 Nov 11.","journal-title":"Int J Multiling Radiat Oncol*Biol*Phys"},{"issue":"3","key":"2869_CR43","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/cam4.1948","volume":"8","author":"JR Robbins","year":"2019","unstructured":"Robbins JR, Schmid RK, Hammad AY, Gamblin TC, Erickson BA. Stereotactic body radiation therapy for hepatocellular carcinoma: practice patterns, dose selection and factors impacting survival. Cancer Med [Internet]. 2019;8(3):928\u201338. Available from: 10.1002\/cam4.1948. 2024 Nov 11.","journal-title":"Cancer Med"},{"issue":"1","key":"2869_CR44","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13014-021-01778-6","volume":"16","author":"T-S Su","year":"2021","unstructured":"Su T-S, Liu Q-H, Zhu X-F, Liang P, Liang S-X, Lai L, et al. Optimal stereotactic body radiotherapy dosage for hepatocellular carcinoma: a multicenter study. Radiat Oncol Lond Engl [Internet]. 2021;16(1):79. Available from: https:\/\/doi.org\/10.1186\/s13014-021-01778-6. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8058965\/. 2024 Sep 5.","journal-title":"Radiat Oncol Lond Engl"},{"issue":"1","key":"2869_CR45","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1186\/s12885-019-6063-9","volume":"19","author":"J Sun","year":"2019","unstructured":"Sun J, Zhang T, Wang J, Li W, Zhang A, He W, et al. Biologically effective dose (BED) of stereotactic body radiation therapy (SBRT) was an important factor of therapeutic efficacy in patients with hepatocellular carcinoma (\u22645 cm). BMC Cancer [Internet]. 2019;19(1):846. Available from: 10.1186\/s12885-019-6063-9. 2024 Nov 9.","journal-title":"BMC Cancer"},{"key":"2869_CR46","doi-asserted-by":"crossref","unstructured":"Kim M, Kay CS, Jang WI, Kim M-S, Lee DS, Jang HS. Prognostic value of tumor volume and radiation dose in moderate-sized hepatocellular carcinoma: a multicenter analysis in Korea (KROG 14-17). Med (Baltim) [Internet]. 2017;96(24):e7202. Available from: https:\/\/doi.org\/10.1097\/MD.0000000000007202. https:\/\/journals.lww.com\/00005792-201706160-00051. 2024 Apr 8.","DOI":"10.1097\/MD.0000000000007202"},{"issue":"3","key":"2869_CR47","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1159\/000505693","volume":"9","author":"W-Y Huang","year":"2020","unstructured":"Huang W-Y, Tsai C-L, Que JY, Lo C-H, Lin Y-J, Dai Y-H, et al. Development and validation of a nomogram for patients with nonmetastatic BCLC stage C hepatocellular carcinoma after stereotactic body radiotherapy. Liver Cancer [Internet]. 2020;9(3):326\u201337. Available from: https:\/\/doi.org\/10.1159\/000505693. 2024 Nov 14.","journal-title":"Liver Cancer"},{"issue":"1","key":"2869_CR48","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13014-021-01761-1","volume":"16","author":"Y Long","year":"2021","unstructured":"Long Y, Liang Y, Li S, Guo J, Wang Y, Luo Y, et al. Therapeutic outcome and related predictors of stereotactic body radiotherapy for small liver-confined HCC: a systematic review and meta-analysis of observational studies. Radiat Oncol Lond Engl [Internet]. 2021;16(1):68. Available from: https:\/\/doi.org\/10.1186\/s13014-021-01761-1. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8034166\/. 2024 Oct 14.","journal-title":"Radiat Oncol Lond Engl"},{"key":"2869_CR49","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejca.2020.04.024","volume":"134","author":"AS Mathew","year":"2020","unstructured":"Mathew AS, Atenafu EG, Owen D, Maurino C, Brade A, Brierley J, et al. Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion. Eur J Criminol Cancer [Internet]. 2020;134:41\u201351. Available from: https:\/\/doi.org\/10.1016\/j.ejca.2020.04.024. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920302276. 2024 Nov 5.","journal-title":"Eur J Criminol Cancer"},{"issue":"2","key":"2869_CR50","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ijrobp.2023.08.015","volume":"118","author":"SH Bae","year":"2024","unstructured":"Bae SH, Chun S-J, Chung J-H, Kim E, Kang J-K, Jang WI, et al. Stereotactic body radiation therapy for hepatocellular carcinoma: meta-analysis and International Stereotactic radiosurgery society Practice guidelines. Int J Multiling Radiat Oncol*Biol*Phys [Internet]. 2024;118(2):337\u201351. Available from: https:\/\/doi.org\/10.1016\/j.ijrobp.2023.08.015. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301623077775. 2024 Nov 15.","journal-title":"Int J Multiling Radiat Oncol*Biol*Phys"},{"key":"2869_CR51","doi-asserted-by":"crossref","unstructured":"Ohri N, Dawson LA, Krishnan S, Seong J, Cheng JC, Sarin SK, et al. Radiotherapy for hepatocellular carcinoma: new indications and directions for future study. JNCI J Natl Cancer Inst [Internet]. 2016;108(9):djw133. Available from: 10.1093\/jnci\/djw133. 2024 Apr 5.","DOI":"10.1093\/jnci\/djw133"},{"key":"2869_CR52","doi-asserted-by":"crossref","unstructured":"Que J, Lin C-H, Lin L-C, Ho C-H. Challenges of BCLC stage C hepatocellular carcinoma: results of a single-institutional experience on stereotactic body radiation therapy. Med (Baltim) [Internet]. 2020;99(32):e21561. Available from: 10.1097\/MD.0000000000021561. 2024 Apr 5.","DOI":"10.1097\/MD.0000000000021561"},{"issue":"13","key":"2869_CR53","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1200\/JCO.2012.44.1659","volume":"31","author":"A Bujold","year":"2013","unstructured":"Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RKS, et al. Sequential phase I and II trials of Stereotactic body radiotherapy for Locally advanced hepatocellular carcinoma. JCO [Internet]. 2013;31(13):1631\u201339. Available from: 10.1200\/JCO.2012.44.1659. 2024 Nov 11.","journal-title":"JCO"},{"key":"2869_CR54","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2147\/JHC.S323302","volume":"8","author":"C-M Liu","year":"2021","unstructured":"Liu C-M, Huang B-S, Yen Y-H, Wang Y-M, Huang E-Y, Hsu H-C, et al. Concurrent sorafenib and radiotherapy versus radiotherapy alone for Locally advanced hepatocellular carcinoma: a propensity-Matched analysis. JHC [Internet]. 2021;8:963\u201373. Available from: https:\/\/doi.org\/10.2147\/JHC.S323302. https:\/\/www.dovepress.com\/concurrent-sorafenib-and-radiotherapy-versus-radiotherapy-alone-for-lo-peer-reviewed-fulltext-article-JHC. 2024 Apr 5.","journal-title":"JHC"},{"issue":"12","key":"2869_CR55","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.3390\/cancers15123164","volume":"15","author":"J Kim","year":"2023","unstructured":"Kim J, Cheng JC-H, Nam T-K, Kim JH, Jang BK, Huang W-Y, et al. Efficacy of liver-directed combined radiotherapy in Locally advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancers [Internet]. 2023;15(12):3164. Available from: https:\/\/doi.org\/10.3390\/cancers15123164. 2024 Apr 8.","journal-title":"Cancers"},{"key":"2869_CR56","unstructured":"Dawson LA, Winter KA, Knox JJ, Zhu AX, Krishnan S, Guha C, et al. Stereotactic body radiotherapy vs sorafenib alone in hepatocellular carcinoma: the NRG Oncology\/RTOG, 1112 phase 3 randomized clinical trial. JAMA Oncol [Internet]. 2024. https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2827892. 2025 Jan 4."},{"key":"2869_CR57","doi-asserted-by":"publisher","first-page":"1098686","DOI":"10.3389\/fonc.2023.1098686","volume":"13","author":"X Qiu","year":"2023","unstructured":"Qiu X, Cai J, Chen H, Yao J, Xiao C, Li R, et al. Chemotherapy combined with radiotherapy can benefit more unresectable HCC patients with portal and\/or hepatic vein invasion: a retrospective analysis of the SEER database. Front Oncol [Internet]. 2023;13:1098686. Available from: https:\/\/doi.org\/10.3389\/fonc.2023.1098686. https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1098686\/full. 2024 Sep 17.","journal-title":"Front Oncol"},{"key":"2869_CR58","doi-asserted-by":"publisher","first-page":"110223","DOI":"10.1016\/j.radonc.2024.110223","volume":"194","author":"F Liu","year":"2024","unstructured":"Liu F, Brown DR, Munley MT. Optimal hypofractionated radiation therapy schemes for early-stage hepatocellular carcinoma. Radiother Oncol [Internet]. 2024;194:110223. Available from: https:\/\/doi.org\/10.1016\/j.radonc.2024.110223. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814024001452. 2024 Nov 5.","journal-title":"Radiother Oncol"},{"issue":"1","key":"2869_CR59","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.prro.2021.09.004","volume":"12","author":"S Apisarnthanarax","year":"2022","unstructured":"Apisarnthanarax S, Barry A, Cao M, Czito B, DeMatteo R, Drinane M, et al. External beam radiation therapy for primary liver cancers: an ASTRO clinical Practice guideline. Pract Radiat Oncol [Internet]. 2022;12(1):28\u201351. Available from: https:\/\/doi.org\/10.1016\/j.prro.2021.09.004. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850021002332. 2024 Apr 3.","journal-title":"Pract Radiat Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-026-02869-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02869-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02869-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T07:55:00Z","timestamp":1786089300000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13014-026-02869-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2869"],"URL":"https:\/\/doi.org\/10.1186\/s13014-026-02869-y","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"28 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Institutional Review Board (IRB) of Jiahui International Hospital in Shanghai, China, approved the present study. The IRB waived the need for informed consent owing to the retrospective nature of the study (reference number: N-JIHSCRJICC2022004-01). This study was conducted in accordance with the ethical guidelines of the Declaration of Helsinki. All methods were performed in accordance with the relevant guidelines and regulations of the captioned IRB.","order":1,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"102"}}